Filing Flows › Viatris (VTRS) › Guidance & outlook
Viatris (VTRS) guidance and outlook
Viatris (VTRS) raised its guidance on Nov 5, 2026: Operating cash flow $2.0B–$2.1B for FY2026; Revenue $100M for Q4 2026; EPS −$2.00 for FY2026; Revenue $14.6B–$14.9B for FY2026. Viatris' 10-Q filed Nov 5, 2026 makes 30 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Operating cash flow | FY2026 | $2.0B–$2.1B | raised |
| Revenue | FY2026 | $287M | new |
| Free cash flow | FY2026 | $895M | new |
| Revenue | Q4 2026 | $100M | new |
| EPS | FY2026 | −$2.00 | reaffirmed |
| Revenue | FY2026 | $14.6B–$14.9B | raised |
| EBITDA | FY2026 | −$1.0M | reaffirmed |
| Free cash flow | FY2026 | −$1.0M | reaffirmed |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- • the possibility that the Company may be unable to achieve the intended or expected benefits of its enterprise-wide strategic review and related cost-saving and restructuring activities within the expected timeframe or at all;
- • the possibility that the Company may be unable to achieve intended or expected benefits in connection with divestitures, acquisitions, strategic alliances, collaborations, or other transactions, or restructuring programs, within the expected timeframes or at all;
- • the possibility that the Company may not complete the proposed acquisition of Pacira within the timeframe it anticipates or at all and, if completed, the possibility that the Company may not realize the anticipated benefits, synergies and operating efficiencies of the proposed acquisition;
- • any changes in or difficulties with the Company’s manufacturing facilities, including with respect to short- or long-term shutdowns, inspections, remediation and restructuring activities, supply chain continuity, inventory management, or the ability to meet anticipated demand;
- • the Company’s failure to achieve expected or targeted future financial and operating performance and results;
- • the effect of any changes in the Company’s or its partners’ customer and supplier relationships and customer purchasing patterns, including customer loss and business disruption being greater than expected following an adverse regulatory action, acquisition or divestiture;
- We expect that any reduction in that funding will have a negative impact on our financial condition, results of operations or cash flows.
- Certain markets in which we do business outside of the U.S. have undergone government-imposed price reductions, and further government-imposed price reductions are expected in the future.
- The Company expects to fund the transaction primarily from excess cash with the remainder from short-term borrowings.
- These restructuring activities are expected to optimize the Company’s commercial capabilities, enabling functions, R&D, medical affairs and regulatory activities, and sourcing, manufacturing and supply chain activities, including inventory optimization.
- As a result, the Company expects a global workforce reduction of up to approximately 10%.
- The Company anticipates that these restructuring activities, as well as associated costs and savings, will be completed primarily over the three years ending 2028.
Viatris' latest quarter
Viatris, Q3 2026: revenue $3.7B (-0.3% year over year), operating margin 7.0%, net loss $325M, operating cash flow $899M. The chart follows the revenue to costs, profit and cash.
Questions
Did Viatris raise or lower its guidance?
Viatris (VTRS) raised its guidance on Nov 5, 2026: Operating cash flow $2.0B–$2.1B for FY2026; Revenue $100M for Q4 2026; EPS −$2.00 for FY2026; Revenue $14.6B–$14.9B for FY2026.
What does Viatris expect?
• the possibility that the Company may be unable to achieve the intended or expected benefits of its enterprise-wide strategic review and related cost-saving and restructuring activities within the expected timeframe or at all; • the possibility that the Company may be unable to achieve intended or expected benefits in connection with divestitures, acquisitions, strategic alliances, collaborations, or other transactions, or restructuring programs, within the expected timeframes or at all; • the possibility that the Company may not complete the proposed acquisition of Pacira within the timefram
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.